3945-85-5

Upstream product

• 93-15-2 1,2-dimethoxy-4-(2-propenyl)benzene 
• 3929-47-3 3-(3,4-dimethoxyphenyl)-1-propanol 
• 1634-04-4 tert-butyl methyl ether 
• 91-16-7 1,2-dimethoxybenzene 
• 105174-63-8 3-bromo-1-(3,4-dimethoxyphenyl)propan-1-one 
• 14737-89-4 3,4-dimethoxy-trans-cinnamic acid 
• 2107-70-2 3,4-methoxycinnamic acid 
• 2316-26-9 3,4-dimethoxycinnamic acid 
• 100157-46-8 3-(3,4-dimethoxyphenyl)-1,1-ethylendioxy-2-propene 
• 100157-47-9 3-(3,4-dimethoxyphenyl)-1,1-ethylendioxypropane 
• 120-14-9 3,4-dimethoxy-benzaldehyde 
• 61871-67-8 3-(3,4-Dimethoxyphenyl)propanal 

Downstream Products

• 68081-10-7 1,5-Bis(3,4-dimethoxyphenyl)-2-methyl-2-pentanol 
• 13575-74-1 4-(3,4-dimethoxyphenyl)butanoic acid 
• 68080-87-5 1-(3,4-Dimethoxy-benzyl)-6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro-naphthalene 
• 1165952-72-6 N-[3'-(3'',4''-dimethoxyphenyl)propyl]-4-vinyloxyazetidin-2-one 
• 74027-78-4 4-(3,4-dimethoxyphenyl)butanamine 
• 57293-20-6 <3-(3,4-dimethoxyphenyl)propyl>triphenylphosphonium bromide 

Relevant academic research and scientific papers

Inter-and intra-molecular organocatalysis of sn2 fluorination by crown ether: Kinetics and quantum chemical analysis

We present the intra-and inter-molecular organocatalysis of SN2 fluorination using CsF by crown ether to estimate the efficacy of the promoter and to elucidate the reaction mechanism. The yields of intramolecular SN2 fluorination of

DOPAMINE RECEPTOR D1 AGONISTS AND METHODS OF USE

Described herein are small molecule agonists of dopamine receptor D1 that inhibit YAP/TAZ, compositions, and methods of using these compounds and compositions.

Structural optimization of natural product nordihydroguaretic acid to discover novel analogues as AcrB inhibitors

Drug efflux pumps confer multidrug resistance to dangerous bacterial pathogens which makes these proteins promising drug targets. Herein, we present initial chemical optimization and structure-activity relationship (SAR) data around a previously described efflux pump inhibitor, nordihydroguaretic acid (NDGA). Four series of novel NDGA analogues that target Escherichia coli AcrB were designed, synthesized and evaluated for their ability to potentiate the activity of antibiotics, to inhibit AcrB-mediated substrate efflux and reduce off-target activity. Nine novel structures were identified that increased the efficacy of a panel of antibiotics, inhibited drug efflux and reduced permeabilization of the bacterial outer and inner membranes. Among them, WA7, WB11 and WD6 possessing broad-spectrum antimicrobial sensitization activity were identified as NDGA analogues with favorable properties as potential AcrB inhibitors, demonstrating moderate improvement in potency as compared to NDGA. In particular, WD6 was the most broadly active analogue improving the activity of all four classes of antibacterials tested.

Mo-Based Oxidizers as Powerful Tools for the Synthesis of Thia- and Selenaheterocycles

A highly efficient synthetic protocol for the synthesis of thia- and selenaheterocycles has been developed. By employing a MoCl5-mediated intramolecular dehydrogenative coupling reaction, a broad variety of structural motifs was isolated in yields up to 94 %. The electrophilic key transformation is tolerated by several labile moieties like halides and tertiary alkyl groups. Due to the use of disulfide or diselenide precursors, a high atom efficiency was achieved.

Investigation of dopamine analogues: Synthesis, mechanistic understanding, and structure-property relationship

Dopamine, perhaps the simplest molecule that covalently links catechol and amine, together with its derivatives, has shown impressive adhesive and coating properties with its polymers. However, the scope of the molecules is rather limited, and the polymer

AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF

Provided is a novel amine compound represented by the following formula (I) having a superior peripheral blood lymphocyte decreasing action and superior in the immunosuppressive action, rejection suppressive action and the like, which shows decreased side effects of, for example, bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or a hydrate thereof, or a solvate thereof. wherein each symbol is as defined in the specification.

A novel and efficient synthesis of dihydrexidine

An efficient synthesis of the dopamine D1 selective full agonist dihydrexidine has been achieved in high yields and requiring no chromatographic separations via a facilitated intramolecular Henry cyclization of a (nitropropyl)benzophenone and subsequent diastereomerically selective reduction of the resulting tricyclic ni- troalkene. Georg Thieme Verlag Stuttgart.

Urokinase inhibitors

Compounds having the formula are inhibitors of urokinase and are useful in the treatment of diseases in which urokinase plays a role. Also disclosed are urokinase-inhibiting compositions and a method of inhibiting urokinase in a mammal.

Ukokinase inhibitors

Compounds having the formula are inhibitors of urokinase and are useful in the treatment of diseases in which urokinase plays a role. Also disclosed are urokinase-inhibiting compositions and a method of inhibiting urokinase in a mammal.

BENZAZEPINE-, BENZOXAZEPINE- AND BENZOTHIAZEPINE-N-ACETIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Compounds with neutral endopeptidase (NEP) inhibitory activity corresponding to the formula I STR1 in which R 1 is a lower alkoxy-lower-alkyl group whose lower alkoxy radical is substituted by a lower alkoxy group, or a phenyl-lower-alkyl or phenyloxy-lower-alkyl group which can optionally be substituted in the phenyl ring by lower alkyl, lower alkoxy or halogen, or a naphthyl-lower-alkyl group, A is CH 2, O or S,R 2 is hydrogen or halogen,R. sup.3 is hydrogen or halogen,R 4 is hydrogen or a group forming a biolabile ester, andR 5 is hydrogen or a group forming a biolabile ester, and the physiologically acceptable acid addition salts thereof.